דפו מדרול 40 מגמל ישראל - עברית - Ministry of Health

דפו מדרול 40 מגמל

pfizer pfe pharmaceuticals israel ltd - methylprednisolone acetate - תרחיף להזרקה - methylprednisolone acetate 40 mg/ml - methylprednisolone - methylprednisolone - for the treatment of conditions responsive to steroid injection therapy.

אילומדין ישראל - עברית - Ministry of Health

אילומדין

bayer israel ltd - iloprost - תרכיז להכנת תמיסה לאינפוזיה - iloprost 0.1 mg/ml - iloprost - iloprost - peripheral arterial occlusive disease (stage 3 and 4 of fontaine's classification) in advanced arteriosclerosis, in whom surgery or angioplasty therapy is not possible.thromboangitis obliterans (buerger's disease) with critical limb ischemia in cases where revascularisation is not indicated and severe disabling raynaud's phenomenon .

טרקליר 62.5 מג ישראל - עברית - Ministry of Health

טרקליר 62.5 מג

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

טרקליר 62.5 מג ישראל - עברית - Ministry of Health

טרקליר 62.5 מג

j-c health care ltd - bosentan as monohydrate - טבליות מצופות פילם - bosentan as monohydrate 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

טרקליר 125 מג ישראל - עברית - Ministry of Health

טרקליר 125 מג

j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

טרקליר 125 מג ישראל - עברית - Ministry of Health

טרקליר 125 מג

j-c health care ltd - bosentan as monohydrate - טבליות מצופות פילם - bosentan as monohydrate 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease

ווליבריס 5 מג ישראל - עברית - Ministry of Health

ווליבריס 5 מג

glaxo smith kline (israel) ltd - ambrisentan - טבליות מצופות פילם - ambrisentan 5 mg - ambrisentan - volibris is indicated for the treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity . efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.

ווליבריס 10 מג ישראל - עברית - Ministry of Health

ווליבריס 10 מג

glaxo smith kline (israel) ltd - ambrisentan - טבליות מצופות פילם - ambrisentan 10 mg - ambrisentan - volibris is indicated for the treatment of patients with pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity . efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease.

רווטיו ישראל - עברית - Ministry of Health

רווטיו

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 20 mg - sildenafil - sildenafil - for adults > 18 years: treatment of primary pulmonary hypertension (pph) pulmonary hypertension (ph) associated with connective tissue disease (ctd) or ph following surgical repair at least 5 years previously of atrial septal defect (asd) ventricular septal defect (vsd) patent ductus arteriosus (pda) or aorto-pulmonary window.

סליידר ישראל - עברית - Ministry of Health

סליידר

unipharm ltd, israel - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 20 mg - sildenafil - sildenafil - for adults > 18 years: indicated for treatment of primary pulmonary hypertension (pph) pulmonary hypertension (ph) associated with connective tissue disease (ctd) or ph following surgical repair at least 5 years previously of atrial septal defect (asd) ventricular septal defect (vsd) patent ductus arteriosus (pda) or aorto-pulmonary window.